دورية أكاديمية
Pulmonary function three to five months after hospital discharge for COVID-19: a single centre cohort study.
العنوان: | Pulmonary function three to five months after hospital discharge for COVID-19: a single centre cohort study. |
---|---|
المؤلفون: | Krueger T; Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands., van den Heuvel J; Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands., van Kampen-van den Boogaart V; Department of Pulmonology, VieCuri Medical Centre, Venlo, The Netherlands., van Zeeland R; Department of Pulmonology, VieCuri Medical Centre, Venlo, The Netherlands., Mehagnoul-Schipper DJ; Department of Intensive Care, VieCuri Medical Centre, Venlo, The Netherlands., Barten DG; Department of Emergency Medicine, VieCuri Medical Centre, Venlo, The Netherlands., Knarren L; Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands., Maas AFG; Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands., Wyers CE; Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands., Gach D; Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands.; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands., Schols AMWJ; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands., Beijers RJHCG; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands., van den Bergh JP; Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands.; Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands., van Osch FHM; Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands. fvosch@viecuri.nl.; Department of Epidemiology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. fvosch@viecuri.nl. |
المصدر: | Scientific reports [Sci Rep] 2023 Jan 13; Vol. 13 (1), pp. 681. Date of Electronic Publication: 2023 Jan 13. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
مواضيع طبية MeSH: | COVID-19*/complications, Humans ; Cohort Studies ; Patient Discharge ; Lung ; Hospitals ; Follow-Up Studies |
مستخلص: | Some COVID-19 survivors suffer from persistent pulmonary function impairment, but the extent and associated factors are unclear. This study aimed to characterize pulmonary function impairment three to five months after hospital discharge and the association with disease severity. Survivors of COVID-19 after hospitalization to the VieCuri Medical Centre between February and December 2020 were invited for follow-up, three to five months after discharge. Dynamic and static lung volumes, respiratory muscle strength and diffusion capacity were measured. The cohort comprised 257 patients after a moderate (n = 33), severe (n = 151) or critical (n = 73) COVID-19 infection with a median follow-up of 112 days (interquartile range 96-134 days). The main sequelae included reduced diffusion capacity (36%) and reduced maximal expiratory pressure (24%). Critically ill patients were more likely to have reduced diffusion capacity than moderate (OR 8.00, 95% CI 2.46-26.01) and severe cases (OR 3.74, 95% CI 1.88-7.44) and lower forced vital capacity (OR 3.29, 95% CI 1.20-9.06) compared to severe cases. Many COVID-19 survivors, especially after a critical disease course, showed pulmonary function sequelae, mainly DLCO impairments, three to five months after discharge. Monitoring is needed to investigate the persistence of these symptoms and the longer-term implications of the COVID-19 burden. (© 2023. The Author(s).) |
References: | Respir Med. 2021 Jun;182:106394. (PMID: 33901787) J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716) EClinicalMedicine. 2020 Aug;25:100463. (PMID: 32838236) Lancet Respir Med. 2022 Sep;10(9):863-876. (PMID: 35568052) Front Med (Lausanne). 2021 Sep 03;8:702635. (PMID: 34540862) Am J Respir Crit Care Med. 2021 Feb 1;203(3):371-374. (PMID: 33326353) JAMA Intern Med. 2020 Jul 1;180(7):934-943. (PMID: 32167524) Biol Proced Online. 2020 Aug 4;22:19. (PMID: 32774178) EClinicalMedicine. 2021 Aug;38:101019. (PMID: 34308300) Clin Microbiol Infect. 2021 Jun;27(6):892-896. (PMID: 33662544) JAMA. 2020 Aug 25;324(8):782-793. (PMID: 32648899) BMJ. 2021 May 19;373:n1098. (PMID: 34011492) Arch Bronconeumol. 2021 Apr;57:59-61. (PMID: 34629656) Thorax. 2021 Apr;76(4):396-398. (PMID: 33172844) N Engl J Med. 2015 Sep 24;373(13):1241-9. (PMID: 26398072) BMJ. 2020 Mar 26;368:m1198. (PMID: 32217618) Lancet. 2021 Jan 16;397(10270):220-232. (PMID: 33428867) Eur Respir J. 2021 Jul 22;58(1):. (PMID: 33574077) Anesth Analg. 2015 Feb;120(2):373-80. (PMID: 25360481) Ann Am Thorac Soc. 2021 Jul;18(7):1253-1255. (PMID: 33472019) JAMA. 2020 Aug 11;324(6):603-605. (PMID: 32644129) Lancet Microbe. 2021 Jan;2(1):e13-e22. (PMID: 33521734) Emerg Microbes Infect. 2020 Dec;9(1):2190-2199. (PMID: 32940572) BMC Pulm Med. 2022 May 16;22(1):196. (PMID: 35578190) BMJ. 2020 Oct 23;371:m3862. (PMID: 33097561) Eur Respir J. 2017 Sep 11;50(3):. (PMID: 28893868) Lancet Respir Med. 2021 Jul;9(7):747-754. (PMID: 33964245) Thorax. 2021 Apr;76(4):402-404. (PMID: 33273023) Eur Respir J. 2012 Dec;40(6):1324-43. (PMID: 22743675) Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143) ERJ Open Res. 2020 Oct 26;6(4):. (PMID: 33257910) Infect Dis (Auckl). 2020 Sep 10;13:1178633720952076. (PMID: 32973375) Eur J Clin Invest. 2021 Aug;51(8):e13603. (PMID: 33998683) Pulmonology. 2021 Jul-Aug;27(4):328-337. (PMID: 33262076) Lancet Reg Health Eur. 2021 Sep;8:100186. (PMID: 34386785) Eur Respir J. 2020 Jun 18;55(6):. (PMID: 32381497) |
تواريخ الأحداث: | Date Created: 20230113 Date Completed: 20230117 Latest Revision: 20230328 |
رمز التحديث: | 20230328 |
مُعرف محوري في PubMed: | PMC9839688 |
DOI: | 10.1038/s41598-023-27879-8 |
PMID: | 36639404 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2045-2322 |
---|---|
DOI: | 10.1038/s41598-023-27879-8 |